• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • Articles
    • News
    • Events
    • Resources
    • M&C Reacts
  • Contact Us
Marks & Clerk logo
Marks & Clerk logo
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • Articles
  • News
  • Events
  • Resources
  • M&C Reacts
Photo: Nicholas Fischer

Nicholas Fischer

Managing Associate

Europe
London

Get in contact

+44 20 7420 0250 nfischer@marks-clerk.com
vCard

Nick is an Associate at Marks & Clerk Law and patent litigator with experience advising across a variety of fields encompassing life sciences, chemistry, telecommunications, engineering and medicinal devices. Nick also has experience advising on regulatory issues in the life sciences sector, including supplementary protection certificates.

Nick’s degree in Cell Biology, including a year spent in the lab during his Master’s degree, means he is well equipped to assist with complex technical disputes with a high level of scientific or technical content.  

Nick trained and qualified as a solicitor at a leading London IP firm before joining Marks & Clerk Law in January 2020.

Alongside his work commitments, Nick sits on the committee of IP Ability, and is a Stambassador for the charity Action for Stammering Children.

Outside of work, Nick is an avid rugby fan, still lacing up his boots when he can, and sings in a choir in London.

Connect with Nicholas via LinkedIn or get in touch!

Experience

  • Life Sciences Sector: experienced in pharmaceuticals and biotechnology including therapeutic antibodies, vaccines, small molecule drugs, and medical devices.
  •  Mechanical: experienced in a variety of mechanical patents including telehandlers.
  • Other experience: advice relating to supplementary protection certificates and other regulatory issues including data/market exclusivity and orphan drug designations.

Key cases

  • Merck Sharp & Dohme v Wyeth
  • Merck Sharp & Dohme v Pfizer
  • Regeneron and Teva v Pfizer
  • JCB v Manitou

Nicholas Fischer works in the following sectors

Biotechnology

Chemical

Medical devices

Pharmaceutical

Telecommunications




Specialist in

  • Patents
  • Chemistry
  • Medical Technologies
  • Litigation & Dispute Resolution
  • Energy & Environment
  • Life Sciences

Qualifications

Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford (2017)

Qualified as a Solicitor in England & Wales (2016)

Legal Practice Course, BPP London (2013)

Graduate Diploma in Law, BPP London (2012)

MSc Plant Cell Biology, University of Durham (2011)

BSc (Hons) Cell Biology, University of Durham (2010)

Search our people

Latest articles by Nicholas Fischer

Biotech Lab Test Tubes
Article
- 28 January 2022

Parties’ duty to keep the Patents Court informed about EPO proceedings

Mr Justice Meade recently handed down judgment in the ongoing Neurim v Mylan (now named Viatris) saga. This judgment followed an expedited three-day trial of preliminary issues and is also notable for imposing a new duty on parties to litigation before the Patents Court.
Read more
Article
- 12 October 2021

A willing FRAND Licensee must commit to take a FRAND licence Optis Cellular v Apple Retail [2021] EWHC 2564 (Pat)

In a lengthy and complex decision reaching over 80 pages and one that will be welcomed by holders of standard essential patents (SEPs), Mr Justice Meade has given judgment in the latest in a series of trials in the UK’s Patents Court between Optis and Apple concerning Optis’ SEPs and the FRAND obligations which apply to them. Two previous trials had established that two of Optis’ SEPs were valid, essential and infringed. One of those patents had expired, the other had not. A trial is due to take place in June 2022 (“Trial E”), at which the court will decide what the terms of a global FRAND licence should be and whether Optis’ approach to the negotiations with Apple breached competition law.
Read more
Article
- 12 October 2021

Mr Justice Meade highlights the importance of confidentiality when dealing with draft judgments

Mr Justice Meade recently handed down a short but important judgment dealing with issues of confidentiality which arose following circulation (but before hand-down) of a draft judgment.
This decision related to a suspected leak of the draft judgment from an earlier trial between the parties (Optis Cellular v Apple Retail [2021] EWHC 2564 (Pat), known as “Trial F”), handed down at the end of September as part of an ongoing SEP and FRAND dispute.
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Lexology
  • Mondaq